Alaunos Therapeutics Touts Early Clinical Response For Its Cancer Cell Therapy
Alaunos Therapeutics Inc (NASDAQ:TCRT) announced early clinical findings from its ongoing TCR-T Library Phase 1/2 trial. “We are excited to announce…
Ironwood Shares Positive Top-line Data From Late-Stage Functional Constipation Candidate Study In Patients Aged 6-17 Years
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced positive top-line data from its Phase 3 clinical trial evaluating LINZESS (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional constipation (FC).
Emergent Shares Decline Following Commencement Of Initial-Stage Lassa Virus Vaccine Candidate Study
Emergent BioSolutions (NYSE: EBS) has dosed first patient in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV in healthy subjects.
EBS-LASV is a recombinant VSV-vectored Lassa virus vaccine candidate being evaluated for prevention of disease caused by Lassa virus infection.
MannKind Shares Fall After Completing Initial Stage Lung Disease Study
MannKind Corporation (NASDAQ: MNKD) has successfully completed a Phase 1 study of clofazimine inhalation suspension (MNKD 101), an inhalation treatment option for nontuberculous mycobacterial (NTM) lung disease.
Iveric Bio Shares Shoot Higher Following Positive Top-line Data From Late-Stage Geographic Atrophy Study
Iveric Bio (NASDAQ: ISEE) announced positive topline results from the second Phase 3 clinical trial of Zimura (avacincaptad pegol) for the treatment of geographic atrophy (GA).
Ironwood’s Constipation Drug Shows Efficacy In Pediatric Patients
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) announced topline data from a Phase 3 trial evaluating Linzess (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional constipation.
IDEAYA Shares Climb As Initial Stage Uveal Melanoma Study Kick-off In Australia
IDEAYA Biosciences (NASDAQ: IDYA) has initiated Investigator Sponsored Trial to evaluate darovasertib as monotherapy in neo-adjuvant and adjuvant settings in primary, non-metastatic uveal melanoma (UM) patients.
Moleculin Receives FDA Orphan Drug Designation Of WP1122 For The Treatment Of Glioblastoma Multiforme
- Glioblastoma is the most aggressive malignant primary brain tumor with serious unmet medical need
HOUSTON, Sept. 6, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX)
FDA And Health Canada Clear IND For FSD Pharma To Proceed With Phase 2 Trial Of FSD201 For Nociplastic Pain Associated With Idiopathic Mast Cell Activation Syndrome
FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to
Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-004, Shows Potential To Reduce Lung Inflammation In Asthma And Allergy Disorders
Treatment with HT-004 significantly reduced lung inflammation after ovalalbumin (OVA) challenge in an asthma and allergy mouse model
NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc.